tbuckley/cabot-search huggingface dataset:
In Reply
Authors: Lauren E. Abrey, Leah Ben-Porat, Katherine S. Panageas, Joachim Yahalom, Walter Curran, Christopher Schultz, Steven Leibel, Diana Nelson, Minesh Mehta, Lisa M. DeAngelis
Journal: Journal of Clinical Oncology (2007)

variables was prospectively planned in a phase II trial, 5 and their prognostic value has been confirmed in that trial.In fact, the variables included in the IELSG score can be routinely collected for PCNSL patients if prospectively planned.The score proposed by Abrey et al 1 is simple, but simplicity could be to the detriment of accuracy.Present data show that the use of a disease-specific score, which includes LDH serum level, CSF protein level, and involvement of deep regions of the brain other than age and PS will result in a better risk stratification of PCNSL patients enrolled in prospective trials.The IELSG prognostic score, in fact, follows the model of the International Prognostic Index for aggressive lymphomas, 8 which includes variables related to aggressiveness, extension and site of disease other than age and PS.We hope that a more diffuse use of the IELSG prognostic score could have a similar impact on clinical practice and prospective trials than those eventually demonstrated for the International Prognostic Index.
An extraordinary fluctuating paediatric illness.
Journal: BMJ (1976)

The patient, the fourth of five children, is now aged 6.His father developed symptoms of anxiety, irritability, excessive tiredness, and occasional aggression when he was 27.When he was 37 mild schizo- phrenic disorganisation was diagnosed.During the next two years he became increasingly apt to fall asleep.Narcolepsy was diagnosed, but his wife was convinced that he had a brain tumour.When he was 40 a craniotomy showed a large cystic yellow tumour indenting the posterior portion of the third ventricle.The tumour was partially removed and a ventriculoatrial drainage system made with a Pudenz valve to relieve his obstructive hydrocephalus.Histologically the tumour was a pinealoma.Seven years later, although in good physical health, his intelligence quotient is 75.His behaviour is impulsive and over- emotional and includes periods of aggression to his wife and children.He had one isolated grand-mal seizure four years ago.His wife has looked after all the family with great devotion.In 1974, when aged 42, she complained of difficulty in swallowing and was admitted to a psychiatric hospital.There she lost 5 kg in 10 days before discharging herself against medical advice.She insisted that she had throat cancer.She persuaded her doctor to admit her to a private nursing home, and a hypopharyngeal carcinoma was found, which responded to x-ray treatment.She has no symptoms at present. THE PATIENTIn 1972, at the age of 2 years 9 months, the boy began to have morning vomiting and often rubbed his head as though in pain.He had frequent episodes of screaming.Over a six-week period he became unsteady and fell frequently.His mother was certain that he had a brain tumour of a similar nature to his father's.
Abstract 1150: Targeted immunoPET imaging of prostate cancer using a novel CD133 antibody
Authors: Paige Glumac, Aaron LeBeau
Journal: Cancer Research (2019)

Abstract Prostate cancer is one of the most frequently diagnosed malignancies and the second leading cause of cancer related death among American men. Aggressive variant prostate cancer (AVPC) accounts for approximately 33% of all prostate cancer-related deaths and is characterized by visceral metastasis, minimal responses to current therapies, and poor overall prognosis. The current disease monitoring strategy for AVPC is positron emission tomography - computed tomography (PET/CT) with [18F]-fluorodeoxyglucose (FDG), which is not specific to prostate cancer cells and thus is inadequate in many cases. As such, novel targeted imaging agents are urgently needed for earlier detection and better monitoring of AVPC. The transmembrane glycoprotein, CD133, is overexpressed in AVPC and we have identified a single chain variable fragment, termed HA10, which preferentially recognizes a glycosylation-independent epitope on CD133. Further characterization of HA10 revealed that it was able to identify CD133 in cells, patient tissue samples, and in vivo xenograft models using fluorescent imaging. The purpose of this study was to investigate the performance of the radioimmunoconjugate, 89Zr-HA10, for µPET/CT imaging in preclinical models of prostate cancer. HA10 was conjugated to p-SCN-Deferoxamine (DFO) and then radiolabeled with [89Zr]Zr-oxalate at room temperature. Parental (CWR-R1) and CD133-transduced (CWR-R1CD133) prostate cancer cell lines were implanted subcutaneously into male athymic nu/nu mice. Mice were administered 180 µCi of 89Zr-HA10 via tail vein injection and µPET/CT imaging was conducted at 24, 48, 72, and 144 hours post-injection. The 89Zr-HA10 construct was successfully labeled with a radiochemical purity &amp;gt;99% as determined by radio-thin layer chromatography. Specificity of 89Zr-HA10 was demonstrated for CD133-positive tumors with strong tumoral uptake detection from 24-72 hours. Furthermore, the margins of the CD133-positive tumors were clearly defined following 3D reconstruction of the µPET/CT images. These studies suggest that 89Zr-HA10 is a promising immunoPET imaging agent for AVPC and potentially other CD133-positive cancer subtypes. Moreover, the use of 89Zr-HA10 as a radiotracer will facilitate a more selective strategy for diagnosis and disease monitoring of these patients compared to the conventional FDG radiotracer. Further studies seek to evaluate the potential of 89Zr-HA10 to detect small metastatic lesions in vivo. Citation Format: Paige Glumac, Aaron LeBeau. Targeted immunoPET imaging of prostate cancer using a novel CD133 antibody [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1150.
Physiological adjustments to altitude changes
Authors: D. B. Dill
Journal: JAMA (1968)

Physiological adaptation to high altitude involves rapid responses in respiration and slower responses in nervous, muscular, and cardiovascular system. An excellent criterion of adaptation is measurement of the capacity for supplying oxygen to tissues, oxygen consumption (Vo<sub>2</sub>maximum). Such measurements reveal four stages of response. At 10,000 feet, for example, stage 1 is reached in minutes; Vo<sub>2</sub>max declines 10%. In one to three days, stage 2, it declines another 10%; this is the stage of unpleasant subjective responses. In a few weeks, stage 3, performance approaches the level of stage 1. Red blood cell volume increases in stage 4, reaching its maximum after a year or more. Performance improves pari passu: Eventually sea-level performance can be achieved at 13,200 feet. The above course of events is idealized. Individuals vary widely in rate of adaptation; the amount of exercise plays a role, and age is a factor. Above
Drug Reactions
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The role of schools in Healthy People 2000
Authors: M. A. Heeb
Journal: JAMA (1995)

<h3>To the Editor.</h3> —It was encouraging to read the article "<i>Healthy People 2000</i>at Mid Decade" by Drs McGinnis and Lee,<sup>1</sup>but I was unable to find any mention of the importance of health education in our schools as an important component of disease prevention in our society. In August 1989, the National Association of State Boards of Education and the American Medical Association formed a national commission on the role of the school and the community in improving adolescent health. The commission demonstrated that for the first time in the history of this country, young people are less healthy and less prepared to take their places in society than their parents were. In June 1992, with support provided by the American Cancer Society, 100 representatives of 37 national health education and social service agencies gathered to develop an action plan that would move forward an agenda these organizations
Free graft augmentation urethroplasty for bulbar urethral strictures – Which technique is best? A systematic review
Authors: R. Barratt, G. Chan, R. La Rocca, K. Dimitropoulos, F.E. Martins, F.C. Juanatey, T.J. Greenwell, M. Waterloos, S. Riechardt, N. Osman, F. Esperto, A. Ploumidis, N. Lumen
Journal: European Urology (2021)
Some Recent Issues in Low-Exposure Radiation Epidemiology
Authors: Brian MacMahon
Journal: Environmental Health Perspectives (1989)

Three areas of activity in the field of low-level radiation epidemiology have been reviewed. They concern the questions of cancer risk related to antenatal X-ray exposure, occupational radiation exposure, and residence in areas of real or supposed increased levels of radiation. Despite the a priori unlikelihood of useful information developing from studies in any of these areas, such investigations are being pursued, and the results are proving to be stimulating. Much important information will be forthcoming in the near future.
A CASE OF EPILEPSY CURED (APPARENTLY) BY THE CORRECTION OF AN ERROR OF REFRACTION.... BY J. ELLIOTT COLBURN, M.D....
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hare's Text-Book of Practical Therapeutics.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stuart Coverley
Journal: BMJ (2005)

Founder of the Northern Ireland Renal ServiceMollie McGeown overcame gender prejudice in 1950s Northern Ireland medicine to build a career that changed the lives of thousands of people affected by kidney failure.After completing an MD thesis on endocarditis followed by a PhD in biochemistry, she was awarded a five year Medical Research Council fellowship and went on to develop an international reputation in calcium metabolism, hyperparathyroidism, and kidney stone disease.In 1959 she was appointed to set up a dialysis service for Northern Ireland and carried out the first successful dialysis on a uraemic patient later that year.This was a pivotal moment for patients in Northern Ireland with kidney failure.Over 200 patients in Northern Ireland at that time died each year from this cause.In 1971 a young woman treated by Mollie for pregnancy related renal failure founded the Northern Ireland Kidney Research Fund, which has to date raised £3m (€4.38m; $5.6m).Mollie was the patron of this fund up to her death.
Abstract 1063: Intracardiac Injection of Epoetin-α Upregulates Stem Cell Chemoattractant Gene Expression In a Rat Myocardial Infarction Model
Authors: Christian Klopsch, Dario Furlani, Ralf Gäbel, Klaus Wagner, Weiwei Wang, Lee-lee Ong, Wenzhong Li, Horst Nizze, Ulf Titze, Andreas Lendlein, Karola Lützow, Ren-Ke Li, Nan Ma, gustav steinhoff
Journal: Circulation (2007)

Emerging evidence suggests that Erythropoietin (EPO) protects the myocardium from ischemic injury and promotes beneficial remodelling. However, the role of EPO and its receptor (EPO-R) in mediating cardiac regeneration remains unclear. We hypothese that stem cell homing and proliferation modulated by EPO could contribute to its cardio-protective effects. Epoetin-α (3000 U/kg) was injected along the infarction border after the induction of a rat myocardial infarction (MI) by permanent ligation of the left descending coronary artery. At six weeks after MI, cardiac function was measured by pressure-volume loops in left and right ventricles. Infarction size, angiogenesis and pathologic effects were evaluated. Gene expressions of EPO-R, SDF-1α, CXCR-4, c-kit, eNOS, TNF-α, IL-8, Integrin-β and CdK4 were analyzed by RT-PCR at different time points of the first week (24h, 48h, 96h and 7 days). We found EPO treatment improved left ventricular function both at baseline levels and under Dobutamine stress (tau, cardiac output, stroke work, ejection fraction, dp/dt maximum and minimum, n=11–14, p&lt;0.05) and decreased right ventricular wall stress (maximum and endsystolic pressure, n=5– 8, p&lt;0.05). Infarction size was reduced from 27.8±3.4% to 20.1±2.8% (n=6 – 8, p&lt;0.01). Capillary density was increased from 257.7±24.5 to 338.5±35.9 (vessels per square mm, n=6 – 8, p&lt;0.05). Mortality was decreased from 29.0% to 22.2% (n=53– 69). EPO-R was down regulated in infarcted, peri-infarcted and non infarcted areas at all time points (n=7, p&lt;0.05). Cardiac SDF-1α, CXCR-4 and eNOS gene expressions were increased at 24 hours. C-kit was up regulated significantly at 48 hours compared to 24 hours in the EPO treated hearts. In untreated hearts, c-kit expression remained constant. Proinflammatory cytokines (TNF-β, IL-8 and Integrin-γ) were down regulated. Cell cycle re-entry marker (CdK4) was increased at 24 hours in non infarcted zones. In conclusion, we demonstrate intramyocardium Epoetin-α injection induces an earlier up regulation of stem cell chemoattractants, reduces inflammation, enhances angiogenesis and restores heart function after MI.
Hypocapnia
Authors: John G. Laffey, Brian P. Kavanagh
Journal: New England Journal of Medicine (2002)

Hypocapnia, defined as low partial pressure of arterial blood carbon dioxide, is usually well tolerated and often has no apparent effects. Although transient induction of hypocapnia can be lifesaving in patients with severe intracranial hypertension or neonatal pulmonary-artery hypertension, prolonged hypocapnia may adversely influence outcome. In this article, Laffey and Kavanagh review the prevalence and pathogenesis of hypocapnia, as well as the role of hypocapnia in clinical medicine.
This Week in &lt;EMPH&gt;JAMA&lt;/EMPH&gt;
Journal: JAMA (2005)

James C. Garbutt, MD; Henry R. Kranzler, MD; Stephanie S. O’Malley, PhD; David R. Gastfriend, MD; Helen M. Pettinati, PhD; Bernard L. Silverman, MD; John W. Loewy, PhD; Elliot W. Ehrich, MD; for the Vivitrex Study Group
Reports of Officers
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells
Authors: Lynsey M Whilding, Ana C Parente-Pereira, Tomasz Zabinski, David M Davies, Roseanna M G Petrovic, Y Vincent Kao, Shobhit A Saxena, Alex Romain, Jose A Costa-Guerra, Shelia Violette, Hiroaki Itamochi, Sadaf Ghaem-Maghami, Sabari Vallath, John F Marshall, John Maher
Journal: Molecular Therapy (2017)

(Molecular Therapy 25, 259–273; January 4, 2017) The authors regret that King’s Health Partners Confidence in Concept was inadvertently omitted as a funding source in the Acknowledgments section of the original paper. The corrected Acknowledgments section appears below and has been corrected online. We apologize for any inconvenience this may have caused. This research was supported by Worldwide Cancer Research (13- 1017), Breast Cancer Now (2010MayPR33), Pancreatic Cancer UK (A16648), King’s Health Partners Confidence in Concept (MC_PC_14105), the Experimental Cancer Medicine Centre at King’s College London, and by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. We thank Anthony Walker and Mike Garrison for useful discussions. Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T CellsWhilding et al.Molecular TherapyDecember 8, 2016In BriefMaher and colleagues describe a chimeric antigen receptor (CAR) directed against the αvβ6 integrin, a target that is aberrantly expressed in diverse solid tumors but that exhibits highly restricted expression in normal tissues. αvβ6-re-targeted CAR T cells elicit therapeutic activity in several tumor models while maintaining an excellent safety profile. Full-Text PDF Open Archive
Raising the Bar for Procedural Competency Among Hospitalists
Authors: Daniel N. Ricotta, Jakob I. McSparron, Grace C. Huang
Journal: Annals of Internal Medicine (2019)

Letters1 October 2019Raising the Bar for Procedural Competency Among HospitalistsDaniel N. Ricotta, MD, Jakob I. McSparron, MD, and Grace C. Huang, MDDaniel N. Ricotta, MDHarvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts (D.N.R., G.C.H.)Search for more papers by this author, Jakob I. McSparron, MDUniversity of Michigan, Ann Arbor, Michigan (J.I.M.)Search for more papers by this author, and Grace C. Huang, MDHarvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts (D.N.R., G.C.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0449 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Dr. Weigel for his informative perspective on the state of procedural training in internal medicine at a rural community program. We agree that the scope of practice among internists and internists in training will vary according to structure and available resources. The lack of subspecialists (such as interventional radiologists) and open intensive care unit models in particular environments may, indeed, generate the procedural volume necessary for residents and hospitalists to develop and maintain skills, with the caveat that procedural experience does not necessarily equal competence (1). Wherever possible, we still recommend the use of lower-cost simulation ...References1. Barsuk JH, Cohen ER, Feinglass J, et al. Residents' procedural experience does not ensure competence: a research synthesis. J Grad Med Educ. 2017;9:201-8. [PMID: 28439354] doi:10.4300/JGME-D-16-00426.1 CrossrefMedlineGoogle Scholar2. Ricotta DN, Smith CC, McSparron JI, et al. When old habits train a new generation: findings from a national survey of internal medicine program directors on procedural training. Am J Med Qual. 2018;33:383-90. [PMID: 29185357] doi:10.1177/1062860617743786 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts (D.N.R., G.C.H.)University of Michigan, Ann Arbor, Michigan (J.I.M.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-3007. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRaising the Bar for Procedural Competency Among Hospitalists Jonathan T. Crocker , Caleb P. Hale , Anita Vanka , Daniel N. Ricotta , Jakob I. McSparron , and Grace C. Huang Raising the Bar for Procedural Competency Among Hospitalists Joseph G. Weigel Metrics 1 October 2019Volume 171, Issue 7Page: 524-525KeywordsDisclosureHospitalistsIntensive care unitsRadiologistsResidencySafetySub-specialty care ePublished: 1 October 2019 Issue Published: 1 October 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...